Venetoclax

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Multiple Myeloma · Phase 3 · investigational in the US

Also approved (2)
JP
  • Treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Product first approved 2019PMDA
EU
  • Venclyxto is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL): in combination with acalabrutinib with or without obinutuzumab in combination with obinutuzumab in combination with ibrutinib Venclyxto in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy. Venclyxto monotherapy is indicated for the treatment of CLL: in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor,...
Product first approved 2016EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (57)
Acute Myeloid Leukemia
NCT07948122 · University Hospital, Toulouse
2027-01-04 – 2037-12-31 · Acute Myeloid Leukemia
What this study did
NCT04628026 · University of Ulm
2022-09-13 – 2032-02 · Acute Myeloid Leukemia
What this study did
NCT07007312 · Kura Oncology, Inc.
2025-09-26 – 2031-11 · Acute Myeloid Leukemia (AML)
What this study did
NCT07539818 · Institute of Hematology & Blood Diseases Hospital, China
2026-05-15 – 2031-04-01 · AML
What this study did
NCT05183035 · PedAL BCU, LLC
2022-10-01 – 2031-04 · Acute Myeloid Leukemia
What this study did
NCT07407140 · Institute of Hematology & Blood Diseases Hospital, China
2026-04-30 – 2030-12-31 · AML, Adult
What this study did
NCT07396480 · First Affiliated Hospital of Zhejiang University
2026-03-01 – 2030-06-30 · Venentoclax, Myeloid Malignancies, Conditioning, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Acute Myeloid Leucemia, Myeldysplastic Syndrome (MDS)
What this study did
NCT07478991 · PETHEMA Foundation
2026-07-02 – 2030-04 · Acute Myeloid Leukemia, Adult
What this study did
NCT07407660 · Peking University People's Hospital
2026-02-01 – 2030-02-01 · Acute Myeloid Leukemia
What this study did
NCT07735117 · Ruijin Hospital
2026-07-30 – 2029-07-31 · Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
What this study did
NCT07469046 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2026-04-10 – 2029-03-31 · Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years)
What this study did
NCT07075016 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2025-08-05 – 2029-03 · Acute Myeloid Leukemia
What this study did
NCT07132684 · Institute of Hematology & Blood Diseases Hospital, China
2025-08-31 – 2028-08-30 · AML, Adult
What this study did
NCT07486479 · The First Affiliated Hospital of Soochow University
2026-03-10 – 2027-12-31 · Acute Myeloid Leukemia (AML)
What this study did
NCT07514936 · Chinese PLA General Hospital
2024-11-18 – 2027-12-31 · Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients
What this study did
NCT07712848 · The Second Affiliated Hospital of Kunming Medical University
2026-04-01 – 2027-12-01 · AML (Acute Myeloid Leukemia)
What this study did
NCT06990321 · Yehui Tan
2025-06-01 – 2026-12-31 · Acute Myeloid Leukemia (AML), Elderly
What this study did
NCT05264883 · The First Affiliated Hospital with Nanjing Medical University
2021-03-01 – 2025-02-28 · Acute Myeloid Leukemia
What this study did
NCT05177731 · Chen Suning
2022-03-01 – 2024-12-31 · AML, Adult, Chemotherapy Effect
What this study did
NCT05457361 · Nanfang Hospital, Southern Medical University
2022-03-01 – 2023-12-31 · Venetoclax Combined With Azacitidine Plus Homoharringtonine, Venetoclax Combined With Azacitidine
What this study did
Chronic Lymphocytic Leukemia
NCT05947851 · Merck Sharp & Dohme LLC
2023-08-08 – 2035-07-01 · Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL
What this study did
NCT05057494 · AstraZeneca
2022-09-12 – 2029-04-10 · Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
What this study did
NCT03462719 · Janssen Research & Development, LLC
2018-04-17 – 2029-04-05 · Leukemia, Lymphocytic, Chronic, B-Cell
What this study did
NCT04269902 · National Cancer Institute (NCI)
2021-03-02 – 2028-10-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT03701282 · National Cancer Institute (NCI)
2019-02-12 – 2028-05-07 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT05197192 · German CLL Study Group
2022-04-19 – 2028-05 · Chronic Lymphocytic Leukemia
What this study did
NCT03336333 · BeiGene
2017-10-31 – 2027-10-31 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT04965493 · Loxo Oncology, Inc.
2021-09-20 – 2027-10 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT03737981 · National Cancer Institute (NCI)
2019-01-31 – 2026-12-29 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT03406156 · AbbVie
2018-08-10 – 2023-07-12 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
What this study did
NCT02756611 · AbbVie
2016-06-22 – 2022-03-11 · Chronic Lymphocytic Leukemia
What this study did
Multiple Myeloma
Phase 2/3 (22)
Acute Myeloid Leukemia
NCT03013998 · Beat AML, LLC
2016-11 – 2032-12 · Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
What this study did
NCT07425808 · European Organisation for Research and Treatment of Cancer - EORTC
2026-12-01 – 2032-02-01 · AML (Acute Myeloid Leukemia)
What this study did
NCT05404906 · The First Affiliated Hospital of Soochow University
2022-06-25 – 2030-06 · Acute Myeloid Leukemia (AML) in Remission
What this study did
NCT06972641 · Ruijin Hospital
2025-06-10 – 2030-03-31 · AML, MDS
What this study did
VEN+IDAC vs IDAC in AMLenrolling by invitation
NCT07537257 · Guangdong Second Provincial General Hospital
2026-04-01 – 2029-04-01 · AML (Acute Myelogenous Leukemia)
What this study did
NCT07264010 · Nanfang Hospital, Southern Medical University
2025-12-01 – 2028-12-30 · Acute Myeloid Leukaemia (AML), Measurable Residual Disease (MRD)
What this study did
NCT04256317 · Taiho Oncology, Inc.
2020-05-21 – 2028-11-01 · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
What this study did
NCT06544109 · The First Affiliated Hospital of Soochow University
2023-08-01 – 2028-08-01 · Acute Promyelocytic Leukemia
What this study did
NCT05939180 · The First Affiliated Hospital of Soochow University
2024-04-01 – 2028-05-13 · Acute Myeloid Leukemia
What this study did
NCT05805098 · The First Affiliated Hospital of Soochow University
2023-03-01 – 2028-03-01 · Acute Myeloid Leukemia
What this study did
NCT04708054 · M.D. Anderson Cancer Center
2021-10-21 – 2027-12-31 · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
What this study did
NCT07255872 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-04-02 – 2027-12 · Acute Myeloid Leukemia
What this study did
NCT05356169 · Institute of Hematology & Blood Diseases Hospital, China
2022-05-19 – 2027-10-15 · Acute Myeloid Leukemia
What this study did
NCT06285136 · The Second Affiliated Hospital of Kunming Medical University
2024-03-01 – 2026-03-01 · Acute Myeloid Leukemia, Adult
What this study did
Chronic Lymphocytic Leukemia
NCT03801525 · TG Therapeutics, Inc.
2019-05-16 – 2022-12-20 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Other / comorbidity
NCT06855810 · Institute of Hematology & Blood Diseases Hospital, China
2025-03-11 – 2031-06 · Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
What this study did
NCT06764238 · Institute of Hematology & Blood Diseases Hospital, China
2025-01-03 – 2031-06 · Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
What this study did
NCT03868722 · Copenhagen University Hospital, Rigshospitalet
2019-10-11 – 2030-07-31 · CLL
What this study did
NCT07052422 · Nanfang Hospital, Southern Medical University
2025-07-15 – 2029-12-31 · Older Patients, Myeloid Malignancies, Conditioning, Hematopoietic Stem Cell Transplantation (HSCT)
What this study did
NCT03984448 · National Cancer Institute (NCI)
2019-10-22 – 2028-08-13 · Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
Phase 2 (307)
Acute Myeloid Leukemia
NCT07437950 · National Cancer Institute (NCI)
2026-09-25 – 2034-09-22 · Acute Myeloid Leukemia
What this study did
NCT05955261 · St. Jude Children's Research Hospital
2023-07-25 – 2034-03 · Acute Myeloid Leukemia
What this study did
NCT07710534 · Virginia Commonwealth University
2026-09-16 – 2033-12-31 · Relapsed / Refractory AML, High Risk Myelodysplastic Syndrome, High Risk Myeloproliferative Neoplasms
What this study did
NCT07664839 · Shen yang
2026-07-01 – 2032-05-31 · Acute Myeloid Leukemia, NPM1 Mutation, IDH1 Mutation, IDH2 Mutation
What this study did
NCT05431257 · Copenhagen University Hospital, Rigshospitalet
2022-05-24 – 2031-09-01 · Acute Myeloid Leukemia
What this study did
NCT05442216 · Joshua Zeidner
2024-05-01 – 2031-07-21 · Acute Myeloid Leukemia
What this study did
NCT07078591 · Beijing 302 Hospital
2025-06-20 – 2031-06 · Acute Myeloid Leukemia
What this study did
NCT05554419 · National Cancer Institute (NCI)
2027-01-04 – 2030-12-31 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
What this study did
NCT06598384 · Navy General Hospital, Beijing
2024-09 – 2030-09 · Acute Myeloid Leukemia
What this study did
NCT05904106 · Technische Universität Dresden
2024-04-07 – 2030-09 · Acute Myeloid Leukemia
What this study did
NCT07949370 · Dana-Farber Cancer Institute
2027-03-06 – 2030-07-31 · Relapsed or Refractory Acute Myeloid Leukemia (AML)
What this study did
NCT07672262 · The First Affiliated Hospital of Soochow University
2026-06-01 – 2030-06-01 · Acute Myeloid Leukemia, Intermediate Risk Acute Myeloid Leukemia, Consolidation Therapy
What this study did
NCT02115295 · M.D. Anderson Cancer Center
2014-05-19 – 2030-05-31 · Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Blasts 10 Percent or More of Peripheral Blood White Cells, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
What this study did
NCT07755202 · Florian Kuchenbauer
2026-09-01 – 2030-05-01 · Acute Myeloid Leukemia, AML With FLT3 Mutation
What this study did
NCT07153497 · National Cancer Institute (NCI)
2026-11-27 – 2030-04-26 · Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT06696183 · Technische Universität Dresden
2025-04-25 – 2030-04 · AML - Acute Myeloid Leukemia
What this study did
NCT06456463 · Stemline Therapeutics, Inc.
2025-01-14 – 2030-02-11 · Acute Myeloid Leukemia
What this study did
NCT07423104 · University of Rochester
2026-12-31 – 2030-02-01 · Acute Myeloid Leukemia (AML)
What this study did
NCT06084819 · Chinese PLA General Hospital
2023-08-01 – 2030-01-31 · Relapsed/Refractory Acute Myeloid Leukemia
What this study did
NCT06221683 · Children's Hospital of Soochow University
2024-01-01 – 2029-12 · AML, Childhood, Acute Myeloid Leukemia
What this study did
NCT07060001 · The Methodist Hospital Research Institute
2026-04-09 – 2029-12 · Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)
What this study did
NCT07867626 · Rutgers, The State University of New Jersey
2026-09-30 – 2029-12 · Acute Myeloid Leukaemia (AML)
What this study did
NCT07754799 · Institute of Hematology & Blood Diseases Hospital, China
2026-09-30 – 2029-09-30 · Acute Myeloid Leukemia (AML)
What this study did
NCT07228273 · OHSU Knight Cancer Institute
2025-12-12 – 2029-08-24 · Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT05564390 · National Cancer Institute (NCI)
2024-06-18 – 2029-05-15 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
What this study did
NCT06317649 · National Cancer Institute (NCI)
2024-09-27 – 2029-05-15 · Acute Myeloid Leukemia
What this study did
NCT07023588 · Yehui Tan
2025-06-01 – 2029-05 · Acute Myeloid Leukemia (AML)
What this study did
NCT07507825 · First People's Hospital of Hangzhou
2026-03-31 – 2029-03-31 · Acute Myeloid Leukemia (AML)
What this study did
NCT06782542 · Justin Watts, MD
2026-03-31 – 2029-03-31 · Acute Myeloid Leukemia, IDH1 Mutation
What this study did
NCT04968015 · French Innovative Leukemia Organisation
2022-05-25 – 2029-01-31 · Acute Myeloid Leukemia
What this study did
NCT07514832 · Beijing 302 Hospital
2026-04-15 – 2028-12-31 · AML (Acute Myeloid Leukemia)
What this study did
NCT06470841 · Navy General Hospital, Beijing
2024-09-20 – 2028-12 · Acute Myeloid Leukemia
What this study did
NCT02781883 · Bio-Path Holdings, Inc.
2016-05 – 2028-12 · Acute Myeloid Leukemia (AML)
What this study did
NCT06014489 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2024-01-17 – 2028-12 · AML, Adult
What this study did
NCT07783100 · The First Affiliated Hospital of Xiamen University
2026-11-11 – 2028-11-30 · Relapsed or Refractory Acute Myeloid Leukemia
What this study did
NCT07425782 · The First Affiliated Hospital of Soochow University
2026-02-01 – 2028-11-26 · Acute Myeloid Leukemia, Consolidation Therapy, Venentoclax, High Risk, Hematopoietic Stem Cell Transplant (HSCT)
What this study did
NCT06557421 · Institut Paoli-Calmettes
2026-02-04 – 2028-11-01 · Acute Myeloid Leukemia
What this study did
NCT04746235 · M.D. Anderson Cancer Center
2021-02-22 – 2028-10-31 · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT06635681 · Institute of Hematology & Blood Diseases Hospital, China
2024-09-29 – 2028-10-01 · AML (Acute Myelogenous Leukemia)
What this study did
NCT06532552 · The First Affiliated Hospital of Soochow University
2024-07-29 – 2028-08-01 · Acute Myeloid Leukemia, Adult, Newly Diagnosed
What this study did
NCT06511882 · H. Lee Moffitt Cancer Center and Research Institute
2024-11-07 – 2028-08 · Acute Myeloid Leukemia
What this study did
NCT06537843 · Hospital Municipal São José
2023-12-01 – 2028-07-01 · Acute Myeloid Leukemia
What this study did
NCT06483906 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2024-07-02 – 2028-07-01 · Acute Myeloid Leukemia
What this study did
NCT06668558 · Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
2024-12-16 – 2028-07 · Acute Myeloid Leukemia
What this study did
NCT07605949 · UNC Lineberger Comprehensive Cancer Center
2026-12 – 2028-07 · Leukemia Acute Myeloid
What this study did
NCT06744556 · Institute of Hematology & Blood Diseases Hospital, China
2025-01-21 – 2028-06-01 · AML
What this study did
NCT07642453 · Hematology department of the 920th hospital
2026-06-01 – 2028-06-01 · Acute Myeloid Leukemia (AML)
What this study did
NCT06504459 · OHSU Knight Cancer Institute
2025-01-03 – 2028-05-01 · Acute Monocytic Leukemia, Acute Myeloid Leukemia
What this study did
Phase 1/2 (128)
Acute Myeloid Leukemia
NCT07604233 · M.D. Anderson Cancer Center
2026-11-30 – 2033-06-03 · Myeloid Leukemia
What this study did
NCT07726576 · University Hospital, Bordeaux
2026-09 – 2031-12 · Leukemia, Myeloid, Acute
What this study did
NCT07148180 · Jacqueline Garcia, MD
2026-02-02 – 2030-12-31 · Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers
What this study did
NCT07926607 · Second Affiliated Hospital of Nanchang University
2026-11-01 – 2029-12-31 · Acute Myeloblastic Leukemia
What this study did
NCT06548230 · M.D. Anderson Cancer Center
2025-03-05 – 2029-12-01 · Myelodysplastic Syndrome(MDS), Acute Myelogenous Leukemia (AML)
What this study did
NCT05807932 · Heinrich-Heine University, Duesseldorf
2023-06-26 – 2029-04-30 · Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
What this study did
NCT04657081 · Taiho Oncology, Inc.
2021-02-09 – 2028-12-31 · Acute Myeloid Leukemia
What this study did
NCT04797767 · University of Washington
2022-02-04 – 2028-12-31 · Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myeloid Neoplasm
What this study did
NCT06284486 · M.D. Anderson Cancer Center
2024-09-23 – 2028-12-30 · Acute Myeloid Leukemia
What this study did
NCT06611839 · Institute of Hematology & Blood Diseases Hospital, China
2025-10-17 – 2028-10-01 · AML, IDH1 Mutation, Treatment
What this study did
NCT07486726 · Shanghai Jiao Tong University School of Medicine
2026-03-15 – 2028-10 · Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)
What this study did
NCT04140487 · M.D. Anderson Cancer Center
2019-12-17 – 2028-09-01 · Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm
What this study did
NCT05520567 · Astellas Pharma Global Development, Inc.
2023-01-31 – 2028-07-31 · Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia
What this study did
NCT05010122 · M.D. Anderson Cancer Center
2021-07-08 – 2028-01-30 · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT03661307 · M.D. Anderson Cancer Center
2018-10-31 – 2028-01-01 · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
What this study did
NCT04988555 · Sumitomo Pharma America, Inc.
2022-02-28 – 2027-12-31 · Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
What this study did
NCT04588922 · Sellas Life Sciences Group
2021-05-10 – 2027-12-31 · Hematologic Malignancies
What this study did
NCT07451912 · The First Affiliated Hospital of Soochow University
2025-09-15 – 2027-12 · Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML
What this study did
NCT04581512 · Ellipses Pharma
2020-11-02 – 2027-12 · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
What this study did
NCT04774393 · M.D. Anderson Cancer Center
2021-05-24 – 2027-11-29 · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT03471260 · M.D. Anderson Cancer Center
2018-03-19 – 2027-09-30 · Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT03214562 · M.D. Anderson Cancer Center
2017-09-26 – 2027-09-30 · High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT05226455 · Groupe Francophone des Myelodysplasies
2022-11-23 – 2027-09-01 · MDS, AML
What this study did
NCT06129734 · Benjamin Tomlinson
2025-07-28 – 2027-09 · Myeloid Malignancy, Acute Myeloid Leukemia
What this study did
NCT06561880 · Institute of Hematology & Blood Diseases Hospital, China
2024-10-08 – 2027-08-31 · FLT3 Gene Mutation, AML
What this study did
NCT03850574 · Aptose Biosciences Inc.
2019-03-11 – 2027-04 · Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2, Chronic Myelomonocytic Leukemia
What this study did
NCT04068597 · CellCentric Ltd.
2019-08-09 – 2027-03-31 · Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
What this study did
NCT05428969 · Faron Pharmaceuticals Ltd
2022-06-02 – 2027-03 · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
What this study did
NCT04086264 · AbbVie
2019-11-06 – 2027-02 · Acute Myeloid Leukemia
What this study did
NCT03862157 · M.D. Anderson Cancer Center
2019-02-27 – 2027-01-31 · Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Eosinophilic Leukemia, Not Otherwise Specified, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Unclassifiable, Overt Primary Myelofibrosis, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Prefibrotic/Early Primary Myelofibrosis
What this study did
NCT05360160 · M.D. Anderson Cancer Center
2022-10-14 – 2026-12-01 · Acute Myeloid Leukemia
What this study did
NCT05211570 · AB Science
2022-06-01 – 2026-12 · Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia
What this study did
NCT04817241 · National Cancer Institute (NCI)
2022-02-10 – 2026-11-05 · Acute Myeloid Leukemia
What this study did
NCT02392572 · M.D. Anderson Cancer Center
2015-11-03 – 2026-08-14 · Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
What this study did
NCT06382168 · Delta-Fly Pharma, Inc.
2024-06-12 – 2026-06-30 · Leukemia, Myeloid, Acute
What this study did
NCT05522192 · Hui Zeng
2022-07-21 – 2026-05 · Relapsed or Refractory Acute Myeloid Leukemia
What this study did
NCT04278768 · Curis, Inc.
2020-07-06 – 2026-04-01 · Acute Myelogenous Leukemia, Myelodysplastic Syndrome
What this study did
NCT05503355 · BioSight Ltd.
2022-08-17 – 2025-12-01 · AML, Adult
What this study did
NCT06563804 · Servier Bio-Innovation LLC
2025-02-25 – 2025-10-09 · Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, Chronic Myelomonocytic Leukemia (CMML)
What this study did
NCT04330820 · Technische Universität Dresden
2020-04-06 – 2025-09-24 · Relapsed Adult AML, Refractory AML
What this study did
NCT06508489 · Sanofi
2024-08-13 – 2025-08-08 · Acute Myeloid Leukemia
What this study did
NCT06449482 · Institute of Hematology & Blood Diseases Hospital, China
2023-05-05 – 2025-03-30 · Acute Myeloid Leukemia, Adult
What this study did
NCT04435691 · M.D. Anderson Cancer Center
2020-07-28 – 2025-03-25 · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT06150040 · Centre Leon Berard
2024-09-11 – 2025-02-18 · Acute Myeloid Leukemia Refractory
What this study did
NCT04874194 · M.D. Anderson Cancer Center
2021-12-17 – 2024-09-16 · Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Biphenotypic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
What this study did
NCT03932318 · Actinium Pharmaceuticals
2023-03 – 2024-09 · Acute Myeloid Leukemia, Relapsed Adult AML
What this study did
NCT03867682 · Actinium Pharmaceuticals
2020-01-15 – 2024-06 · Acute Myeloid Leukemia, Relapsed Adult AML
What this study did
NCT04029688 · Hoffmann-La Roche
2020-01-27 – 2024-05-06 · Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
What this study did
NCT05893472 · ZePing Zhou
2023-04-01 – 2024-04-01 · Acute Myeloid Leukemia, Venetoclax
What this study did
Phase 1 (186)
Acute Myeloid Leukemia
NCT07320235 · Douglas Tremblay
2026-01-02 – 2035-06-15 · Relapsed Acute Myeloid Leukemia
What this study did
NCT07828535 · Institute of Hematology & Blood Diseases Hospital, China
2026-10-30 – 2032-12-31 · Acute Myeloid Leukemia (AML)
What this study did
NCT07059975 · Baylor College of Medicine
2025-10-22 – 2031-08 · Acute Myeloid Leukemia, Pediatric AML
What this study did
NCT06448013 · M.D. Anderson Cancer Center
2025-03-07 – 2030-12-31 · Acute Myeloid Leukemia
What this study did
NCT07374029 · David Avigan
2026-02-12 – 2030-10-01 · Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
What this study did
NCT06454409 · City of Hope Medical Center
2025-04-25 – 2030-09-06 · Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
What this study did
NCT07722767 · Cullinan Therapeutics Inc.
2026-10-15 – 2030-08-31 · AML (Acute Myeloid Leukemia)
What this study did
NCT07511062 · Northside Hospital, Inc.
2027-01-31 – 2030-08-01 · Acute Myeloid Leukemia, TP53 Gene Mutation
What this study did
NCT05292664 · Andrew E. Place, MD
2023-03-29 – 2030-07-02 · Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Lymphoblastic Lymphoma, in Relapse, Lymphoblastic Lymphoma, Refractory, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Leukemia of Ambiguous Lineage
What this study did
NCT05735184 · Kura Oncology, Inc.
2023-07-18 – 2030-04 · Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Nucleophosmin 1-mutated Acute Myeloid Leukemia
What this study did
NCT03613532 · Jacqueline Garcia, MD
2018-10-24 – 2030-03-05 · Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable), Hematopoietic Stem Cell Transplant
What this study did
NCT05986240 · Montefiore Medical Center
2024-05-08 – 2030-03 · AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes
What this study did
NCT07283094 · Montefiore Medical Center
2026-02-03 – 2030-02 · Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT07177079 · Kittika Poonsombudlert
2026-03-18 – 2029-12-31 · Acute Myeloid Leukemia
What this study did
NCT05287568 · University of Colorado, Denver
2022-12-19 – 2029-03 · AML
What this study did
NCT07439211 · Jacqueline Garcia, MD
2026-04-13 – 2029-02-01 · Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia, Refractory Leukemia
What this study did
NCT06177067 · St. Jude Children's Research Hospital
2024-04-19 – 2029-02 · Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
What this study did
NCT05263284 · City of Hope Medical Center
2022-10-31 – 2029-01-25 · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT06802523 · National Cancer Institute (NCI)
2026-11-18 – 2028-12-31 · Acute Myeloid Leukemia
What this study did
NCT05342584 · Montefiore Medical Center
2022-05-25 – 2028-12 · Acute Myeloid Leukemia, Myelodysplastic Syndromes
What this study did
NCT04227847 · Seagen, a wholly owned subsidiary of Pfizer
2020-08-07 – 2028-07-03 · Myelodysplastic Syndrome, Acute Myeloid Leukemia
What this study did
NCT06445907 · M.D. Anderson Cancer Center
2025-02-12 – 2028-07-01 · Acute Myeloid Leukemia
What this study did
NCT05834244 · M.D. Anderson Cancer Center
2023-10-26 – 2028-06-30 · Acute Myeloid Leukemia
What this study did
NCT07814339 · Rutgers, The State University of New Jersey
2026-09 – 2028-06 · Acute Myeloid Leukemia
What this study did
NCT06357182 · OHSU Knight Cancer Institute
2024-08-22 – 2028-05-29 · Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia
What this study did
NCT06634394 · Aptevo Therapeutics
2024-10-01 – 2028-03 · Acute Myeloid Leukemia (AML)
What this study did
NCT06651229 · Janssen Research & Development, LLC
2025-03-21 – 2028-02-09 · Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms
What this study did
NCT03874052 · Jennifer Saultz
2019-08-16 – 2027-12-31 · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Secondary Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Secondary Acute Myeloid Leukemia
What this study did
NCT03844815 · University of Chicago
2019-11-18 – 2027-12-10 · Acute Myeloid Leukemia
What this study did
NCT06152809 · Dana-Farber Cancer Institute
2024-02-20 – 2027-11-30 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia, Leukemia, Myeloid
What this study did
NCT06429449 · University of Colorado, Denver
2024-07-21 – 2027-11 · Leukemia, Myeloid Leukemia, Monocytic Leukemia
What this study did
NCT06399640 · Vanderbilt-Ingram Cancer Center
2024-08-14 – 2027-10-01 · Relapsed Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT06514261 · National Cancer Institute (NCI)
2024-12-18 – 2027-09-16 · Acute Myeloid Leukemia
What this study did
NCT04898894 · St. Jude Children's Research Hospital
2021-11-15 – 2027-09 · Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia
What this study did
NCT06372717 · Apollo Therapeutics Ltd
2024-06-04 – 2027-08 · Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia (AML), Newly Diagnosed Acute Myeloid Leukemia (AML)
What this study did
NCT03969446 · City of Hope Medical Center
2020-05-19 – 2027-07-04 · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
What this study did
NCT05453903 · Janssen Research & Development, LLC
2022-10-04 – 2027-06-30 · Leukemia, Myeloid, Acute
What this study did
NCT03041688 · National Cancer Institute (NCI)
2018-02-08 – 2027-06-30 · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
What this study did
NCT06501196 · BlossomHill Therapeutics
2024-06-19 – 2027-06 · Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia, Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia
What this study did
NCT03113643 · Dana-Farber Cancer Institute
2017-06-26 – 2027-05-31 · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm
What this study did
NCT04150887 · OncoVerity, Inc.
2019-12-23 – 2027-05-15 · Leukemia, Myeloid, Acute
What this study did
NCT04603001 · Eli Lilly and Company
2020-11-19 – 2027-05 · Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
What this study did
NCT06007911 · Medical College of Wisconsin
2024-08-31 – 2027-04 · Relapsed Adult AML, Refractory AML
What this study did
NCT05222984 · City of Hope Medical Center
2022-09-16 – 2027-03-02 · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT06763341 · City of Hope Medical Center
2025-07-30 – 2027-01-16 · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT05317403 · Medical College of Wisconsin
2023-03-31 – 2027-01 · Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
What this study did
NCT07044544 · University of Alabama at Birmingham
2025-07-17 – 2027-01 · Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes
What this study did
NCT05001828 · Polaris Group
2022-04-05 – 2027-01 · Acute Myeloid Leukemia, Adult
What this study did
Phase 4 (6)
Acute Myeloid Leukemia
NCT06571825 · He Huang
2024-07-17 – 2028-02-28 · Acute Myeloid Leukemia
What this study did
NCT06763666 · Nanfang Hospital, Southern Medical University
2025-02 – 2025-12 · Relapsed/Refractory AML
What this study did
NCT07773909 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2022-06-01 – 2023-03-01 · Acute Myeloid Leukemia
What this study did
Chronic Lymphocytic Leukemia
NCT04790045 · Paolo Ghia
2023-11-01 – 2026-12-31 · Chronic Lymphocytic Leukemia
What this study did
Early phase / not applicable (38)
Acute Myeloid Leukemia
NCT06841952 · The First Affiliated Hospital of Soochow University
2025-02-15 – 2030-12-15 · AML, Adult
What this study did
NCT07635485 · The First Affiliated Hospital of Soochow University
2026-06-01 – 2029-08-31 · Hypoplastic Acute Myeloid Leukemia, Secondary AML (Adult)
What this study did
NCT07762508 · The First Affiliated Hospital of Soochow University
2026-08 – 2029-07 · Leukemia, Myeloid, Acute(AML), Hematopoietic Stem Cell Transplantation (HSCT)
What this study did
NCT07490288 · Institute of Hematology & Blood Diseases Hospital, China
2026-05-08 – 2029-03-01 · AML
What this study did
NCT07243483 · Centre Leon Berard
2026-01-21 – 2029-01-01 · Acute Myeloid Leukemia
What this study did
NCT07131059 · Institute of Hematology & Blood Diseases Hospital, China
2024-05-11 – 2028-10-30 · AML, Adult
What this study did
NCT07183878 · First Affiliated Hospital of Zhejiang University
2025-08-20 – 2028-08-20 · Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndromes, High-Risk Myelodysplastic Syndromes
What this study did
NCT06536010 · Yang Xiaotian
2021-11-03 – 2028-07-31 · Acute Myeloid Leukemia
What this study did
NCT06265545 · Institute of Hematology & Blood Diseases Hospital, China
2024-02-22 – 2028-06-30 · AML, Refractory, Relapsed
What this study did
NCT05909293 · The First Affiliated Hospital with Nanjing Medical University
2023-04-12 – 2028-05-30 · Acute Myeloid Leukemia
What this study did
NCT06232694 · The First Affiliated Hospital with Nanjing Medical University
2024-01-01 – 2027-12-30 · Acute Myeloid Leukemia
What this study did
NCT06328179 · Huai'an First People's Hospital
2022-05-24 – 2027-12-30 · Acute Myeloid Leukemia
What this study did
NCT06386302 · Institute of Hematology & Blood Diseases Hospital, China
2024-08-05 – 2027-12-30 · AML, Acute Myeloid Leukemia
What this study did
NCT06643962 · Affiliated Hospital of Nantong University
2024-10-31 – 2027-10-31 · Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
What this study did
NCT07244367 · Sohag University
2025-09-01 – 2027-09-01 · Acute Myeloid Leukaemia (AML)
What this study did
NCT07187505 · Anhui Medical University
2025-07-01 – 2027-07-01 · Acute Promyelocytic Leukemia (APL)
What this study did
NCT06090786 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2024-07 – 2027-07 · AML, Adult, Minimal Residual Disease
What this study did
NCT07117422 · The Second Hospital of Hebei Medical University
2025-01-17 – 2027-01-30 · AML, Adult
What this study did
NCT06697327 · Anhui Medical University
2025-02-01 – 2026-08-01 · Leukemia, Myeloid, Acute, Acute Myeloid Leukemia
What this study did
NCT05262465 · guomei
2020-07-01 – 2025-07-01 · Adult Acute Myeloid Leukemia
What this study did
NCT06030089 · Centre Hospitalier Universitaire de Nice
2024-02-26 – 2025-03-03 · Acute Myeloid Leukemia
What this study did
NCT05941585 · Institute of Hematology & Blood Diseases Hospital, China
2023-08-08 – 2025-01-17 · Acute Myeloid Leukemia
What this study did
NCT05471700 · Zhujiang Hospital
2022-09-01 – 2023-04-04 · Leukemia, Myeloid, Acute
What this study did
NCT05053425 · LanZhou University
2021-10-20 – 2023-03-18 · Acute Myeloid Leukemia
What this study did
Chronic Lymphocytic Leukemia
NCT07691047 · Private Hospital of Confluent, France
2026-09-30 – 2029-09-30 · Chronic Lymphoid Leukemia
What this study did
Other / comorbidity
NCT07921550 · Institute of Hematology & Blood Diseases Hospital, China
2026-11-30 – 2035-11-30 · ALL
What this study did
NCT06991920 · Institute of Hematology & Blood Diseases Hospital, China
2026-06-30 – 2032-04-01 · Adult ALL, MPAL
What this study did
NCT07493161 · Institute of Hematology & Blood Diseases Hospital, China
2026-04-10 – 2030-03-30 · Ph+ ALL
What this study did
NCT07454226 · Institute of Hematology & Blood Diseases Hospital, China
2026-05-30 – 2030-03-01 · Ph-Like, Acute Lymphoblastic Leukemia
What this study did
NCT07495631 · Institute of Hematology & Blood Diseases Hospital, China
2026-04-08 – 2030-03-01 · Acute Lymphoblastic Leukemia, Adult
What this study did
NCT06481228 · Institute of Hematology & Blood Diseases Hospital, China
2024-06-04 – 2028-06-01 · Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult
What this study did
NCT06481241 · Institute of Hematology & Blood Diseases Hospital, China
2024-06-10 – 2028-06 · Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult
What this study did
NCT06237192 · National Research Center for Hematology, Russia
2023-04-01 – 2027-09-01 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
What this study did
NCT06192979 · Jin Lu, MD
2024-01-05 – 2027-03-31 · Amyloidosis; Systemic, AL Amyloidosis
What this study did
NCT05657652 · The First Affiliated Hospital of Soochow University
2022-10-01 – 2026-10 · Acute Lymphoblastic Leukemia
What this study did
NCT05863845 · Ruijin Hospital
2023-06-01 – 2025-11-30 · Diffuse Large B Cell Lymphoma
What this study did
Used as active comparator (9)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (8)
Acute Myeloid Leukemia
NCT07925190 · Beijing InnoCare Pharma Tech Co., Ltd.
2026-11-03 – 2030-06 · Acute Myeloblastic Leukemia
What this study did
NCT04229979 · Sellas Life Sciences Group
2021-02-08 – 2026-12 · Acute Myeloid Leukemia
What this study did
NCT03926624 · Delta-Fly Pharma, Inc.
2019-11-22 – 2026-01-07 · Leukemia, Myeloid, Acute
What this study did
Chronic Lymphocytic Leukemia
Phase 2 (1)
Acute Myeloid Leukemia
Appears in other studies (6)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Acute Myeloid Leukemia
NCT06852222 · Janssen Research & Development, LLC
2025-06-04 – 2029-08-15 · Leukemia, Myeloid, Acute
What this study did
NCT05079230 · Gilead Sciences
2022-07-07 – 2024-04-11 · Acute Myeloid Leukemia
What this study did
Phase 2/3 (1)
Phase 2 (1)
Acute Myeloid Leukemia
NCT05603884 · The First Affiliated Hospital of Xiamen University
2022-12-01 – 2026-12-31 · Leukemia, Myeloid, Acute, AML Stage, Adult
What this study did
Phase 1/2 (2)
Acute Myeloid Leukemia
NCT06746519 · Chen Suning
2024-12-25 – 2027-06-30 · Acute Myeloid Leukemia
What this study did
NCT06387420 · Akeso
2024-04-29 – 2027-04 · ACUTE MYELOID LEUKEMIA; AML
What this study did

Competitive landscape

This mechanism is crowded: 10 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Acute Myeloid Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Venetoclax: this drugApprovedSmall moleculeBCL-2Reliable signal
NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed
Azacitidine (Onureg)ApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)Weak signal
NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results).
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Enasidenib (Idhifa)ApprovedSmall moleculeIDH2Partial signal
NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed
Gemtuzumab OzogamicinApprovedAntibody–drug conjugateCD33Partial signal
NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed
NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients.
GilteritinibApprovedSmall moleculeFLT3Partial signal
NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed
GlasdegibApprovedSmall moleculeHedgehog Pathway InhibitorPartial signalNo reviewed efficacy summary in this indication
Ivosidenib (Tibsovo)ApprovedSmall moleculeMutant IDH1Reliable signal
NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis)
Midostaurin (Rydapt)ApprovedSmall moleculeFLT3;KIT;PKC;PDGFRWeak signal
NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed
NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results).
OlutasidenibApprovedSmall moleculeMutant IDH1Weak signalFeatured results are safety only in this race
Orca-T (TREGZI)ApprovedCell therapyAllogeneic engineered T-cell immunotherapyPartial signal
NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5)
QuizartinibApprovedSmall moleculeFLT3Reliable signal
NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2)
RevumenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
Sargramostim (Leukine)ApprovedProtein / enzyme therapeuticGM-CSF receptornot yet gradedNo reviewed efficacy summary in this indication
Tretinoin (Vesanoid)
ApprovedUS marketing discontinued
Small moleculeRARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APLnot yet graded
NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending
VyxeosApprovedSmall moleculeDNA synthesis (cytarabine, antimetabolite) / Topoisomerase IIPartial signal
NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1).
ZiftomenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
131I-ApamistamabPhase 3Monoclonal antibodyCD45Partial signal
NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001
Arsenic Trioxide (QTX-2101)Phase 3Small moleculePML-RARA fusion oncoproteinnot yet gradedNo reviewed efficacy summary in this indication
Arsenic Trioxide (SDK001)Phase 3Small moleculePML-RARA fusion oncoproteinPartial signalNo reviewed efficacy summary in this indication
AzacitidinePhase 3Small moleculeDNMT1 (DNA methyltransferase 1)Partial signal
NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed
BleximenibPhase 3Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
Clifutinib BesylatePhase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
CrenolanibPhase 3Small moleculeFLT3 (including D835/ITD mutants), also PDGFR-alpha/betaReliable signal
NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145)
Galinpepimut-SPhase 3VaccineWT1 (Wilms Tumor-1 protein)Weak signal
NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47%
Inobrodib
Phase 3(overall)
Small moleculeCBP/p300 (bromodomain)not yet gradedNo reviewed efficacy summary in this indication
LisaftoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MocravimodPhase 3Small moleculeSphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)not yet gradedNo reviewed efficacy summary in this indication
RuserontinibPhase 3Small moleculeFLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes)Partial signalNo reviewed efficacy summary in this indication
XY0206Phase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
AnnamycinPhase 2/3Small moleculeTopoisomerase II (TOP2)not yet gradedNo reviewed efficacy summary in this indication
BL-M11D1Phase 2/3Antibody–drug conjugateCD33not yet gradedNo reviewed efficacy summary in this indication
Pivekimab Sunirine (Decnupaz)Phase 2/3Antibody–drug conjugateCD123not yet gradedNo reviewed efficacy summary in this indication
CusatuzumabPhase 2Monoclonal antibodyCD70Weak signal
NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38
FCN-338
Phase 2(overall)
Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Lintuzumab-Ac225Phase 2RadiopharmaceuticalCD33Weak signalNo reviewed efficacy summary in this indication
PegargiminasePhase 2Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminaseWeak signal
NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months
PrexigebersenPhase 2RNA / oligonucleotideGRB2 (growth factor receptor-bound protein 2) mRNAWeak signalFeatured results are safety only in this race
RomaciclibPhase 2Small moleculeCDK8 / CDK19Weak signal
NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response
Sonrotoclax (Beqalzi)Phase 2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
TagraxofuspPhase 2Protein / enzyme therapeuticCD123Weak signalNo reviewed efficacy summary in this indication
VididencelPhase 2VaccineAllogeneic dendritic cell vaccineWeak signal
NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported).
AB8939Phase 1/2Small moleculeTubulinnot yet gradedNo reviewed efficacy summary in this indication
ABD-3001Phase 1/2Small moleculeALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1)not yet gradedNo reviewed efficacy summary in this indication
AlrizomadlinPhase 1/2Small moleculeMDM2Weak signalNo reviewed efficacy summary in this indication
ARD103Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
AZD3632Phase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BexmarilimabPhase 1/2Monoclonal antibodyClever-1not yet gradedNo reviewed efficacy summary in this indication
BG1805Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
BSB-1001Phase 1/2Cell therapyHA-1 (minor histocompatibility antigen)not yet gradedNo reviewed efficacy summary in this indication
CART84Phase 1/2Cell therapyCD84not yet gradedNo reviewed efficacy summary in this indication
CCTx-001Phase 1/2Cell therapyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
CD123 Targeted CAR-NK CellsPhase 1/2Cell therapyCD123Weak signalNo reviewed efficacy summary in this indication
CD123 / CD33 CARTPhase 1/2Cell therapyCD123 / CD33not yet gradedNo reviewed efficacy summary in this indication
CLN-049Phase 1/2Multispecific antibodyFLT3, CD3not yet gradedNo reviewed efficacy summary in this indication
Debio 1562MPhase 1/2Antibody–drug conjugateCD37not yet gradedNo reviewed efficacy summary in this indication
EmavusertibPhase 1/2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
EnzomenibPhase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
LigufalimabPhase 1/2Monoclonal antibodyCD47not yet gradedNo reviewed efficacy summary in this indication
MobinitinibPhase 1/2Small moleculeFLT3 / Aurora kinase A and Bnot yet gradedNo reviewed efficacy summary in this indication
MRX-2843Phase 1/2Small moleculeFlt3/MerTKWeak signalNo reviewed efficacy summary in this indication
OcifisertibPhase 1/2Small moleculePLK4 (Polo-like kinase 4)Weak signalFeatured results are safety only in this race
OlverembatinibPhase 1/2Small moleculeBCR-ABL (also AKT, c-Kit, ERK)not yet gradedNo reviewed efficacy summary in this indication
OrcaGraft (Orca-Q)Phase 1/2Cell therapyTreg-enriched allogeneic haematopoietic stem cell graftnot yet gradedNo reviewed efficacy summary in this indication
RogocekibPhase 1/2Small moleculeCLK (CDC-like kinase family)not yet gradedNo reviewed efficacy summary in this indication
TGRX-814Phase 1/2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
BGB-21447
Phase 1(overall)
Small moleculeBCL-2
not yet graded(overall)
No reviewed efficacy summary in this indication
FXS0683Phase 1Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
LonitoclaxPhase 1Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 69 furthest-along competitors are listed; 62 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(334 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Venetoclax to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (34)
November 2026 (5)
Phase 1Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2026-11 · NCT05053659 · CT.gov ↗
What to watch
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2026-11 · NCT03980171 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-11 · NCT03850574 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2026-11 · NCT04895436 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-11-30 · NCT06152809 · CT.gov ↗
What to watch
December 2026 (29)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12 · NCT06429449 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12 · NCT07044544 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12 · NCT06783790 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2026-12 · NCT03467867 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12 · NCT05955261 · CT.gov ↗
What to watch
Phase 1/2CML,Blast PhaseRecruiting
Est. primary completion 2026-12-01 · NCT06757855 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-01 · NCT05360160 · CT.gov ↗
What to watch
Phase 2Precursor Cell Lymphoblastic Leukemia-LymphomaRecruiting
Est. primary completion 2026-12-01 · NCT06387121 · CT.gov ↗
What to watch
Phase 2T-cell Acute Lymphoblastic Leukemia, RecruitingRecruiting
Est. primary completion 2026-12-01 · NCT05376111 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-01 · NCT06220162 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-01 · NCT06635681 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-01 · NCT07712848 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-30 · NCT04588922 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-30 · NCT06284486 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-30 · NCT06451861 · CT.gov ↗
What to watch
Phase 2Ann Arbor Stage II Follicular Lymphoma, Grade 1 Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma …Recruiting
Est. primary completion 2026-12-30 · NCT06471738 · CT.gov ↗
What to watch
Phase 2/3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2026-12-30 · NCT07264010 · CT.gov ↗
What to watch
Phase 1Lymphoma, B-CellActive not recruiting
Est. primary completion 2026-12-31 · NCT04161248 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT05010772 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT06621212 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2026-12-31 · NCT03513562 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT06466122 · CT.gov ↗
What to watch
Phase 2Myeloproliferative NeoplasmRecruiting
Est. primary completion 2026-12-31 · NCT05074355 · CT.gov ↗
What to watch
Phase 2Blastic Plasmacytoid Dendritic Cell NeoplasmRecruiting
Est. primary completion 2026-12-31 · NCT04216524 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT03629171 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2026-12-31 · NCT04128501 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT06990321 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2026-12-31 · NCT07486479 · CT.gov ↗
What to watch
Phase 4Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2026-12-31 · NCT04790045 · CT.gov ↗
What to watch
2027 (134)
January 2027 (10)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-01 · NCT05317403 · CT.gov ↗
What to watch
Phase 1LeukemiaRecruiting
Est. primary completion 2027-01 · NCT03826992 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-01 · NCT05001828 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-01 · NCT06177067 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-01 · NCT06773208 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-01 · NCT06384261 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-01-01 · NCT04801797 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-01-16 · NCT06763341 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-01-31 · NCT03862157 · CT.gov ↗
What to watch
Phase 3Acute T Lymphoblastic Leukemia (T-ALL)Active not recruiting
Est. primary completion 2027-01-31 · NCT07541755 · CT.gov ↗
What to watch
February 2027 (10)
Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-02 · NCT04086264 · CT.gov ↗
What to watch
Phase 2Chronic Lymphoid LeukemiaActive not recruiting
Est. primary completion 2027-02 · NCT04515238 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-02 · NCT03824483 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-02 · NCT05183035 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-02-01 · NCT06399640 · CT.gov ↗
What to watch
Phase 1/2Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell LymphomaRecruiting
Est. primary completion 2027-02-01 · NCT05861050 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-12 · NCT05391750 · CT.gov ↗
What to watch
Phase 1/2Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-02-12 · NCT04939272 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-02-28 · NCT02846623 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-02-28 · NCT06522386 · CT.gov ↗
What to watch
March 2027 (11)
Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-03 · NCT05428969 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-03 · NCT06129734 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-03 · NCT05650723 · CT.gov ↗
What to watch
Phase 1/2HIV-1-infectionRecruiting
Est. primary completion 2027-03-01 · NCT05668026 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-03-02 · NCT05222984 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-03-08 · NCT06357182 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-03-22 · NCT03710772 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-03-23 · NCT05287568 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-03-31 · NCT04068597 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-03-31 · NCT05554406 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-03-31 · NCT06672146 · CT.gov ↗
What to watch
April 2027 (9)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT05853965 · CT.gov ↗
What to watch
Phase 2Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma …Active not recruiting
Est. primary completion 2027-04 · NCT04450173 · CT.gov ↗
What to watch
Phase 1/2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2027-04-01 · NCT07847957 · CT.gov ↗
What to watch
Phase 2Early T Acute Lymphoblastic Leukemia, T-Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T/Myeloid, NosRecruiting
Est. primary completion 2027-04-01 · NCT07012447 · CT.gov ↗
What to watch
Phase 2/3Acute Myeloid LeukemiaEnrolling by invitation
Est. primary completion 2027-04-01 · NCT07537257 · CT.gov ↗
What to watch
Phase 1B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2027-04-12 · NCT05157971 · CT.gov ↗
What to watch
Phase 2Mantle Cell Lymphoma, Non Hodgkin Lymphoma, Hematologic MalignancyRecruiting
Est. primary completion 2027-04-28 · NCT05529069 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-04-30 · NCT03586609 · CT.gov ↗
What to watch
Phase 3Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-04-30 · NCT03836261 · CT.gov ↗
What to watch
May 2027 (7)
Phase 1Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2027-05 · NCT05386576 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-05 · NCT04419519 · CT.gov ↗
What to watch
Early phase / not applicableALLNot yet recruiting
Est. primary completion 2027-05-01 · NCT07921550 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-05-15 · NCT04150887 · CT.gov ↗
What to watch
Phase 2Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia VariantActive not recruiting
Est. primary completion 2027-05-20 · NCT06311227 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-05-31 · NCT03128879 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-05-31 · NCT04975919 · CT.gov ↗
What to watch
June 2027 (11)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-06 · NCT05986240 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-06 · NCT02899052 · CT.gov ↗
What to watch
Phase 2Marginal Zone LymphomaActive not recruiting
Est. primary completion 2027-06 · NCT04416451 · CT.gov ↗
What to watch
Phase 2B-Cell Acute Lymphoblastic Leukemia, AdultActive not recruiting
Est. primary completion 2027-06-01 · NCT07199855 · CT.gov ↗
What to watch
Phase 2Targeted Therapy, IDH1-Mutated Malignancies, MutationsRecruiting
Est. primary completion 2027-06-01 · NCT07032727 · CT.gov ↗
What to watch
Phase 1/2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-06-24 · NCT03523975 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-06-30 · NCT03041688 · CT.gov ↗
What to watch
Phase 1/2Mantle Cell Lymphoma, Refractory LymphomaRecruiting
Est. primary completion 2027-06-30 · NCT04855695 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-06-30 · NCT04988555 · CT.gov ↗
What to watch
Phase 1/2Mutant IDH1 Inhibitor OlutasidenibRecruiting
Est. primary completion 2027-06-30 · NCT06445959 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-06-30 · NCT06429098 · CT.gov ↗
What to watch
July 2027 (10)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-07 · NCT06372717 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-07 · NCT04447768 · CT.gov ↗
What to watch
Phase 3Myelodysplastic Syndrome (MDS)Active not recruiting
Est. primary completion 2027-07 · NCT04401748 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2027-07 · NCT06090786 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-07-01 · NCT06445907 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-07-01 · NCT02756897 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-07-01 · NCT07187505 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-07-04 · NCT04227847 · CT.gov ↗
What to watch
Phase 3Mantle Cell Lymphoma (MCL)Recruiting
Est. primary completion 2027-07-10 · NCT06496308 · CT.gov ↗
What to watch
Phase 3Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-07-15 · NCT05057494 · CT.gov ↗
What to watch
August 2027 (11)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-08 · NCT06191263 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-08 · NCT07214064 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-08 · NCT03844048 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-08-01 · NCT06532552 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-08-05 · NCT06651229 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-08-10 · NCT04941716 · CT.gov ↗
What to watch
Phase 1/2Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt LymphomaRecruiting
Est. primary completion 2027-08-12 · NCT03223610 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaRecruiting
Est. primary completion 2027-08-20 · NCT07183878 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-08-30 · NCT07132684 · CT.gov ↗
What to watch
Phase 2T Lymphoblastic Leukemia/LymphomaRecruiting
Est. primary completion 2027-08-31 · NCT06712121 · CT.gov ↗
What to watch
Phase 2Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts …Active not recruiting
Est. primary completion 2027-08-31 · NCT05600894 · CT.gov ↗
What to watch
September 2027 (10)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-09 · NCT07451912 · CT.gov ↗
What to watch
Phase 1/2AL AmyloidosisActive not recruiting
Est. primary completion 2027-09 · NCT05451771 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2027-09 · NCT07726576 · CT.gov ↗
What to watch
Phase 3Chronic Lymphoid LeukemiaActive not recruiting
Est. primary completion 2027-09 · NCT04608318 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-09-01 · NCT07743112 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2027-09-30 · NCT07722767 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-09-30 · NCT03471260 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-09-30 · NCT03214562 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-09-30 · NCT05401097 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-09-30 · NCT07514936 · CT.gov ↗
What to watch
October 2027 (9)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-10 · NCT06634394 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2027-10 · NCT07486726 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-10 · NCT06511882 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-10 · NCT07163793 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-10-01 · NCT07374029 · CT.gov ↗
What to watch
Early phase / not applicableMyeloid TumorsNot yet recruiting
Est. primary completion 2027-10-01 · NCT07632170 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-10-11 · NCT06504459 · CT.gov ↗
What to watch
Phase 2T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, RelapseRecruiting
Est. primary completion 2027-10-30 · NCT06686108 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-10-31 · NCT02250937 · CT.gov ↗
What to watch
November 2027 (6)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-11 · NCT06660368 · CT.gov ↗
What to watch
Phase 4Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-11 · NCT07044687 · CT.gov ↗
What to watch
Phase 2/3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-11-01 · NCT04256317 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-11-25 · NCT06917911 · CT.gov ↗
What to watch
Phase 1/2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-11-26 · NCT03331198 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-11-29 · NCT04774393 · CT.gov ↗
What to watch
December 2027 (30)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12 · NCT04581512 · CT.gov ↗
What to watch
Phase 1/2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-12 · NCT04623541 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2027-12 · NCT06470841 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12 · NCT02781883 · CT.gov ↗
What to watch
Phase 2T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute LeukemiaRecruiting
Est. primary completion 2027-12 · NCT06390319 · CT.gov ↗
What to watch
Phase 2/3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12 · NCT07255872 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-01 · NCT06548230 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-12-01 · NCT06958705 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-12-01 · NCT06744556 · CT.gov ↗
What to watch
Phase 1B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia …Active not recruiting
Est. primary completion 2027-12-02 · NCT04872790 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-12-10 · NCT03844815 · CT.gov ↗
What to watch
Phase 2Precursor Cell Lymphoblastic Leukemia-LymphomaRecruiting
Est. primary completion 2027-12-15 · NCT05660473 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-12-15 · NCT05963074 · CT.gov ↗
What to watch
Phase 4Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-30 · NCT06571825 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-30 · NCT06232694 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-30 · NCT06328179 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-30 · NCT06386302 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT03874052 · CT.gov ↗
What to watch
Phase 1Refractory Acute Leukemia, Relapsed Acute Leukemia, Undifferentiated Leukemia, Bi-Phenotypic LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT06466395 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07828535 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT04797767 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT06621199 · CT.gov ↗
What to watch
Phase 2Myelodysplastic Syndromes, Myeloproliferative Chronic Myelomonocytic LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT05365035 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07748455 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07862517 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT07557056 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT05554393 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT07734038 · CT.gov ↗
What to watch
Phase 2/3Older Patients, Myeloid Malignancies, Conditioning, Hematopoietic Stem Cell Transplantation (HSCT)Not yet recruiting
Est. primary completion 2027-12-31 · NCT07052422 · CT.gov ↗
What to watch
Phase 2/3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT04708054 · CT.gov ↗
What to watch
2028 (85)
January 2028 (6)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-01 · NCT07392242 · CT.gov ↗
What to watch
Phase 1B-cell Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-01-01 · NCT06863259 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2028-01-01 · NCT03661307 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaRecruiting
Est. primary completion 2028-01-01 · NCT07243483 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-01-30 · NCT05010122 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaRecruiting
Est. primary completion 2028-01-30 · NCT06265545 · CT.gov ↗
What to watch
February 2028 (5)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-02-01 · NCT07439211 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-02-01 · NCT07407660 · CT.gov ↗
What to watch
Phase 2Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive, CD5 Positive, FCER2 Negative …Active not recruiting
Est. primary completion 2028-02-08 · NCT03946878 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2028-02-09 · NCT06456463 · CT.gov ↗
What to watch
Phase 2Myelodysplastic Syndromes, Leukemia, Myelomonocytic, ChronicActive not recruiting
Est. primary completion 2028-02-14 · NCT05201066 · CT.gov ↗
What to watch
March 2028 (11)
Phase 2Waldenstrom Macroglobulinemia, Treatment NaiveRecruiting
Est. primary completion 2028-03 · NCT05099471 · CT.gov ↗
What to watch
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-03 · NCT06428019 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2028-03-01 · NCT04560322 · CT.gov ↗
What to watch
Early phase / not applicablePh-Like, Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-03-01 · NCT07454226 · CT.gov ↗
What to watch
Early phase / not applicableAcute Lymphoblastic Leukemia, AdultRecruiting
Est. primary completion 2028-03-01 · NCT07495631 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-03-26 · NCT05530421 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-03-31 · NCT07507825 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-03-31 · NCT07783100 · CT.gov ↗
What to watch
Phase 2Lymphoplasmacytic Lymphoma, Waldenstrom MacroglobulinemiaRecruiting
Est. primary completion 2028-03-31 · NCT04840602 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-03-31 · NCT07469046 · CT.gov ↗
What to watch
Early phase / not applicablePh+ ALLRecruiting
Est. primary completion 2028-03-31 · NCT07493161 · CT.gov ↗
What to watch
April 2028 (4)
Phase 1/2Peripheral T Cells Lymphoma (PTCL), Follicular Helper T-Cell LymphomaRecruiting
Est. primary completion 2028-04 · NCT07018752 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-04-01 · NCT07514832 · CT.gov ↗
What to watch
Phase 2Waldenstrom Macroglobulinemia, Lymphoplasmacytic LymphomaRecruiting
Est. primary completion 2028-04-11 · NCT07231952 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-04-25 · NCT05536349 · CT.gov ↗
What to watch
May 2028 (9)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-05 · NCT07283094 · CT.gov ↗
What to watch
Phase 2Lymphoma, Mantle-CellRecruiting
Est. primary completion 2028-05 · NCT06558604 · CT.gov ↗
What to watch
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-05 · NCT05197192 · CT.gov ↗
What to watch
Phase 3Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2028-05-07 · NCT03701282 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaRecruiting
Est. primary completion 2028-05-10 · NCT07131059 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-05-15 · NCT06954987 · CT.gov ↗
What to watch
Phase 2Ph- Acute Lymphoblastic Leukemia (Ph-ALL)Not yet recruiting
Est. primary completion 2028-05-31 · NCT07643103 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-05-31 · NCT07664839 · CT.gov ↗
What to watch
Phase 2Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)Not yet recruiting
Est. primary completion 2028-05-31 · NCT07840976 · CT.gov ↗
What to watch
June 2028 (9)
Phase 1Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-06 · NCT07814339 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2028-06 · NCT06668558 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-06 · NCT07867626 · CT.gov ↗
What to watch
Phase 2/3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-06 · NCT05404906 · CT.gov ↗
What to watch
Phase 1Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-06-01 · NCT07133997 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-06-01 · NCT07642453 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-06-05 · NCT07014917 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-06-30 · NCT05834244 · CT.gov ↗
What to watch
Phase 1Recurrent AL Amyloidosis, Refractory AL AmyloidosisActive not recruiting
Est. primary completion 2028-06-30 · NCT04847453 · CT.gov ↗
What to watch
July 2028 (8)
Phase 2Waldenstrom Macroglobulinemia, Lymphoplasmacytic LymphomaActive not recruiting
Est. primary completion 2028-07 · NCT07387471 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-07 · NCT07605949 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2028-07-02 · NCT05292664 · CT.gov ↗
What to watch
Phase 3CancerActive not recruiting
Est. primary completion 2028-07-05 · NCT03768063 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-07-09 · NCT04169737 · CT.gov ↗
What to watch
Phase 1/2Chronic Myelomonocytic Leukemia, Myelodysplastic SyndromeActive not recruiting
Est. primary completion 2028-07-20 · NCT04655755 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-07-20 · NCT07735117 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2028-07-31 · NCT05520567 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2/3Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma …Active not recruiting
Est. primary completion 2028-08-13 · NCT03984448 · CT.gov ↗
What to watch
September 2028 (5)
Phase 1Myeloproliferative NeoplasmNot yet recruiting
Est. primary completion 2028-09-01 · NCT07679334 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-09-01 · NCT04140487 · CT.gov ↗
What to watch
Phase 2Adult T-cell Leukemia/LymphomaRecruiting
Est. primary completion 2028-09-01 · NCT07159620 · CT.gov ↗
What to watch
Phase 2High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma …Recruiting
Est. primary completion 2028-09-01 · NCT06649812 · CT.gov ↗
What to watch
Phase 2Acute Monocytic LeukemiaRecruiting
Est. primary completion 2028-09-30 · NCT07512700 · CT.gov ↗
What to watch
October 2028 (9)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-10 · NCT07059975 · CT.gov ↗
What to watch
Phase 2Lymphoma, Marginal Zone Lymphoma, MZLRecruiting
Est. primary completion 2028-10 · NCT06510309 · CT.gov ↗
What to watch
Phase 1/2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-10-01 · NCT06644183 · CT.gov ↗
What to watch
Phase 2Diffuse Large B Cell LymphomaNot yet recruiting
Est. primary completion 2028-10-01 · NCT06516978 · CT.gov ↗
What to watch
Phase 2/3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-10-01 · NCT07425808 · CT.gov ↗
What to watch
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-10-01 · NCT04269902 · CT.gov ↗
What to watch
Phase 2T Acute Lymphoblastic Leukemia, T Lymphoblastic LymphomaRecruiting
Est. primary completion 2028-10-31 · NCT00501826 · CT.gov ↗
What to watch
Phase 2Mantle Cell Lymphoma (MCL)Active not recruiting
Est. primary completion 2028-10-31 · NCT05951959 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2028-10-31 · NCT04746235 · CT.gov ↗
What to watch
November 2028 (3)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-11-01 · NCT06557421 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-11-26 · NCT07425782 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP) …Not yet recruiting
Est. primary completion 2028-11-30 · NCT07940621 · CT.gov ↗
What to watch
December 2028 (15)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12 · NCT05342584 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12 · NCT06221683 · CT.gov ↗
What to watch
Phase 2CLL/SLLRecruiting
Est. primary completion 2028-12 · NCT04523428 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12 · NCT06014489 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12 · NCT07060001 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12 · NCT07075016 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12 · NCT07874100 · CT.gov ↗
What to watch
Phase 2Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Recruiting
Est. primary completion 2028-12-10 · NCT07007052 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-12-15 · NCT06841952 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT06448013 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT07177079 · CT.gov ↗
What to watch
Phase 1Refractory Acute Leukemia, Pediatric RelapsedRecruiting
Est. primary completion 2028-12-31 · NCT06397027 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT06191978 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT07148180 · CT.gov ↗
What to watch
Phase 2Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT06317662 · CT.gov ↗
What to watch
2029 (38)
January 2029 (3)
Phase 2Waldenstrom MacroglobulinemiaActive not recruiting
Est. primary completion 2029-01-25 · NCT05734495 · CT.gov ↗
What to watch
Phase 1/2T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic LeukemiaRecruiting
Est. primary completion 2029-01-31 · NCT07311746 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-01-31 · NCT06084819 · CT.gov ↗
What to watch
February 2029 (2)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-02-01 · NCT07423104 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-02-01 · NCT07407140 · CT.gov ↗
What to watch
March 2029 (3)
Phase 1/2CLL/SLLRecruiting
Est. primary completion 2029-03 · NCT05791409 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-03 · NCT04628026 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-03-31 · NCT06782542 · CT.gov ↗
What to watch
April 2029 (3)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-04 · NCT06696183 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-04-14 · NCT07582159 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-04-30 · NCT05807932 · CT.gov ↗
What to watch
May 2029 (5)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-05 · NCT07023588 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-05-01 · NCT07024706 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-05-15 · NCT05564390 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-05-15 · NCT06317649 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-05-31 · NCT07635485 · CT.gov ↗
What to watch
June 2029 (4)
Phase 1Acute Myeloid LeukemiaEnrolling by invitation
Est. primary completion 2029-06 · NCT07014462 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-06-08 · NCT07218510 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-06-24 · NCT07228273 · CT.gov ↗
What to watch
Phase 2Myelodysplastic Neoplasms, TransplantationRecruiting
Est. primary completion 2029-06-30 · NCT07047183 · CT.gov ↗
What to watch
July 2029 (4)
Early phase / not applicableAcute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-07 · NCT07762508 · CT.gov ↗
What to watch
Phase 2Mantle Cell Lymphoma (MCL)Recruiting
Est. primary completion 2029-07-01 · NCT07719556 · CT.gov ↗
What to watch
Phase 2/3CLLRecruiting
Est. primary completion 2029-07-31 · NCT03868722 · CT.gov ↗
What to watch
Early phase / not applicableChronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-07-31 · NCT07691047 · CT.gov ↗
What to watch
August 2029 (1)
Phase 1Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-08-01 · NCT07511062 · CT.gov ↗
What to watch
September 2029 (2)
Phase 1/2Higher-risk Myelodysplastic SyndromesRecruiting
Est. primary completion 2029-09-01 · NCT06471946 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-09-30 · NCT07754799 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-10-01 · NCT07755202 · CT.gov ↗
What to watch
December 2029 (10)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-12 · NCT07154264 · CT.gov ↗
What to watch
Phase 2LALNot yet recruiting
Est. primary completion 2029-12-01 · NCT07522801 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2029-12-01 · NCT07690891 · CT.gov ↗
What to watch
Phase 2Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell LymphomaRecruiting
Est. primary completion 2029-12-30 · NCT05910801 · CT.gov ↗
What to watch
Phase 1T-cell Acute Lymphoblastic Leukemia, LymphomaRecruiting
Est. primary completion 2029-12-31 · NCT07513129 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07926607 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07738887 · CT.gov ↗
What to watch
Phase 2T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic LymphomaRecruiting
Est. primary completion 2029-12-31 · NCT06561074 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07949370 · CT.gov ↗
What to watch
Phase 2/3Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)Recruiting
Est. primary completion 2029-12-31 · NCT06764238 · CT.gov ↗
What to watch
2030 (24)
January 2030 (2)
Phase 1HIV-1Recruiting
Est. primary completion 2030-01 · NCT07481175 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-01-31 · NCT07396480 · CT.gov ↗
What to watch
March 2030 (1)
Phase 2/3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-03-31 · NCT06972641 · CT.gov ↗
What to watch
April 2030 (5)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-04 · NCT05735184 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-04 · NCT07478991 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-04-01 · NCT07539818 · CT.gov ↗
What to watch
Early phase / not applicableAdult ALL, MPALNot yet recruiting
Est. primary completion 2030-04-01 · NCT06991920 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2030-04-26 · NCT07153497 · CT.gov ↗
What to watch
May 2030 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-05-31 · NCT02115295 · CT.gov ↗
What to watch
June 2030 (7)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-06 · NCT07078591 · CT.gov ↗
What to watch
Phase 2Myelodysplastic SyndromesRecruiting
Est. primary completion 2030-06 · NCT07238686 · CT.gov ↗
What to watch
Phase 2/3Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic LymphomaRecruiting
Est. primary completion 2030-06 · NCT06855810 · CT.gov ↗
What to watch
Phase 1/2T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma RefractoryRecruiting
Est. primary completion 2030-06-01 · NCT06810778 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-06-01 · NCT07672262 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-06-17 · NCT07320235 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2030-06-30 · NCT06520098 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-07-21 · NCT05442216 · CT.gov ↗
What to watch
August 2030 (1)
Phase 1Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial SarcomasRecruiting
Est. primary completion 2030-08-29 · NCT07713732 · CT.gov ↗
What to watch
September 2030 (3)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2030-09 · NCT06598384 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-09 · NCT05904106 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2030-09 · NCT07082452 · CT.gov ↗
What to watch
December 2030 (3)
Phase 1Kidney Failure Chronic, Stem Cell Transplant, Stem Cell Transplant Complications, Tolerance, Hematologic CancerRecruiting
Est. primary completion 2030-12 · NCT07358195 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2030-12 · NCT02966756 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2030-12-31 · NCT05554419 · CT.gov ↗
What to watch
2031 (8)
February 2031 (1)
Phase 1Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2031-02-10 · NCT05091424 · CT.gov ↗
What to watch
May 2031 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2031-05 · NCT03314181 · CT.gov ↗
What to watch
June 2031 (2)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2031-06-01 · NCT06967610 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2031-06-03 · NCT07604233 · CT.gov ↗
What to watch
September 2031 (2)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2031-09-01 · NCT05431257 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2031-09-30 · NCT07710534 · CT.gov ↗
What to watch
October 2031 (1)
Phase 1/2Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent …Not yet recruiting
Est. primary completion 2031-10-01 · NCT07175415 · CT.gov ↗
What to watch
November 2031 (1)
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2031-11 · NCT07007312 · CT.gov ↗
What to watch
2032 (6)
February 2032 (2)
Phase 1/2Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent …Recruiting
Est. primary completion 2032-02-01 · NCT05745714 · CT.gov ↗
What to watch
Phase 1/2Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent …Recruiting
Est. primary completion 2032-02-01 · NCT05751044 · CT.gov ↗
What to watch
March 2032 (1)
Phase 1/2Leukemia, LymphomaRecruiting
Est. primary completion 2032-03 · NCT07294677 · CT.gov ↗
What to watch
June 2032 (2)
Phase 2/3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2032-06 · NCT07581002 · CT.gov ↗
What to watch
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2032-06-01 · NCT05947851 · CT.gov ↗
What to watch
December 2032 (1)
Phase 2/3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2032-12 · NCT03013998 · CT.gov ↗
What to watch
2033 (1)
May 2033 (1)
Phase 1/2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2033-05 · NCT07520006 · CT.gov ↗
What to watch
2034 (1)
September 2034 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2034-09-22 · NCT07437950 · CT.gov ↗
What to watch
2035 (1)
December 2035 (1)
Phase 3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2035-12-31 · NCT07948122 · CT.gov ↗
What to watch
2038 (1)
December 2038 (1)
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2038-12-31 · NCT05725200 · CT.gov ↗
What to watch
2040 (1)
December 2040 (1)
Phase 2Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive …Active not recruiting
Est. primary completion 2040-12-31 · NCT02689440 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 July 2025Filing submittedsNDA submitted for venetoclax plus acalabrutinib in untreated CLL
US, FDA · Source ↗